Key result
Membrane depolarization enhances sodium channel blockade, with dronedarone showing ~2-fold greater sensitivity than propafenone.
Why the study?
Antiarrhythmic drug effectiveness is highly variable, and alterations in atrial resting membrane potential induced by low Pitx2 expression may explain this variability across clinically used agents.
Does atrial resting membrane potential modify the effectiveness of sodium channel-blocking antiarrhythmic drugs in preclinical models?
Does atrial resting membrane potential modify the effectiveness of sodium channel-blocking antiarrhythmic drugs in preclinical models?
Identifying and modifying atrial resting membrane potential could represent a novel approach to personalizing and enhancing the effectiveness of antiarrhythmic drugs for atrial fibrillation.
Answers are grounded in this paper and cite their sources.
Membrane potential may modulate antiarrhythmic efficacy in experimental models; leaves open whether targeting it could enhance AF therapy.
BACKGROUND: Although atrial fibrillation ablation is increasingly used for rhythm control therapy, antiarrhythmic drugs (AADs) are commonly used, either alone or in combination with ablation. The effectiveness of AADs is highly variable. Previous work from our group suggests that alterations in atrial resting membrane potential (RMP) induced by low Pitx2 expression could explain the variable effect of flecainide. OBJECTIVE: The purpose of this study was to assess whether alterations in atrial/cardiac RMP modify the effectiveness of multiple clinically used AADs. METHODS: 1.5, primary murine atrial cardiac myocytes, and murine hearts with reduced Pitx2c. RESULTS: hearts, which have a more positive RMP compared to wild type. CONCLUSION: Atrial RMP modifies the effectiveness of several clinically used AADs. Dronedarone is more sensitive to changes in atrial RMP than flecainide or propafenone. Identifying and modifying atrial RMP may offer a novel approach to enhancing the effectiveness of AADs or personalizing AAD selection.
No takes yet. Share an insight, caveat, or question.
Holmes et al. (2021) studied Atrial fibrillation (preclinical models) (n=83). Antiarrhythmic drugs (dronedarone, propafenone, flecainide) vs. Baseline / Control resting membrane potential was evaluated on Sensitivity of peak sodium current (INa) inhibition to resting membrane potential (RMP/VH) (almost 2-fold greater sensitivity to RMP/VH for dronedarone compared to propafenone, p=<0.01). A more positive resting membrane potential enhanced the sodium channel blocking efficacy of propafenone, flecainide, and dronedarone, with dronedarone exhibiting an almost 2-fold greater sensitivity than propafenone.
Synapse has enriched 10 related papers. Consider them for comparative context: